TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report released on Tuesday morning, Benzinga reports. They currently have a $15.00 price objective on the stock. HC Wainwright also issued estimates for TScan Therapeutics’ Q2 2024 earnings at ($0.35) EPS, Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.38) EPS, FY2024 earnings at ($1.41) EPS, FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.26) EPS.

TCRX has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a buy rating and set a $11.00 target price on shares of TScan Therapeutics in a research note on Monday, May 13th. Wedbush reaffirmed an outperform rating and set a $10.00 target price on shares of TScan Therapeutics in a research note on Monday, May 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, TScan Therapeutics has an average rating of Buy and an average target price of $12.00.

TScan Therapeutics Price Performance

Shares of TCRX opened at $8.98 on Tuesday. TScan Therapeutics has a one year low of $1.93 and a one year high of $9.36. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.51 and a current ratio of 5.23. The firm has a 50 day simple moving average of $7.63 and a two-hundred day simple moving average of $6.33.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $7.21 million for the quarter, compared to analysts’ expectations of $2.94 million. TScan Therapeutics had a negative net margin of 653.50% and a negative return on equity of 61.13%. On average, equities research analysts anticipate that TScan Therapeutics will post -1.25 EPS for the current year.

Institutional Trading of TScan Therapeutics

Institutional investors have recently modified their holdings of the business. Pale Fire Capital SE bought a new stake in shares of TScan Therapeutics in the third quarter worth $42,000. Cannon Global Investment Management LLC bought a new stake in shares of TScan Therapeutics in the first quarter worth $139,000. Letko Brosseau & Associates Inc. bought a new stake in TScan Therapeutics during the third quarter valued at $83,000. abrdn plc bought a new stake in TScan Therapeutics during the fourth quarter valued at $1,166,000. Finally, Tocqueville Asset Management L.P. bought a new stake in TScan Therapeutics during the first quarter valued at $1,685,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.